# A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

> **NCT00446602** · PHASE2 · WITHDRAWN · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.**

## Conditions studied

- Myelodysplastic Syndromes
- Anemia

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00446602
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2009-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to company decision to focus resources on a larger, controlled study in this patient population.
- **Last updated:** 2016-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446602, "A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00446602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*